Table 2 The primary outcomes
From: Effect of Ubiquinol supplementation on ovulation induction in Clomiphene Citrate resistance
Outcomes | All patients (N=148) | Group A (N=75) | Group B (N=73) | p-value |
|---|---|---|---|---|
Cases reaching mature follicular size during the study period: | ||||
Cycle 1 | 92 (62.2%) | 45 (60.0%) | 47 (64.4%) | 0.712 |
Cycle 2 | 85 (61.2%) | 42 (59.2%) | 43 (63.2%) | 0.711 |
Cycle 3 | 77 (64.2%) | 38 (62.3%) | 39 (66.1%) | 0.722 |
Number of stimulated cycles during the study period * | ||||
Cycle 1 | 148 | 75 (100%) | 73 (100%) | 1.00 |
Cycle 2 | 139 | 71 (94.7%) | 68 (93.2%) | 0.91 |
Cycle 3 | 120 | 61 (81.3%) | 59 (80.8%) | 0.96 |
Number of follicles ≥ 18 mm in diameter on the day of hCG triggering | 1.19 ± 0.38 | 1.14 ± 0.34 | 1.24 ± 0.37 | 0.51 |
Diameter of dominant follicle (mm) | 20.4 ± 6.3 | 20.3 ± 6.1 | 20.6 ± 5.9 | 0.98 |
Endometrial thickness (mm) on the day of hCG triggering | 9.09 ± 2.77 | 8.98 ± 2.97 | 9.21 ± 2.58 | 0.64 |
Mid-luteal Serum progesterone (ng/mL) | 10.77 ± 4.49 | 10.73 ± 4.42 | 10.82 ± 4.57 | 0.88 |